Hugo Tempelman
Overview
Explore the profile of Hugo Tempelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shilabye P, Scheuermaier K, Vos-Seda A, Barth R, Deville W, Coutinho R, et al.
J Acquir Immune Defic Syndr
. 2025 Feb;
PMID: 39972536
Introduction: HIV/AIDS continues to be a significant health issue in Sub-Saharan Africa, with stigma likely affecting ART adherence, and subsequently viremia, inflammation, and cardiovascular disease (CVD). We investigated the association...
2.
van Ginkel F, Barth R, Tempelman H, Klipstein-Grobusch K, Grobbee D, Scheuermaier K, et al.
South Afr J HIV Med
. 2024 May;
25(1):1523.
PMID: 38725702
Background: Antiretroviral therapy (ART) is associated with weight gain, but this has been shown to be more marked with dolutegravir and other integrase strand transfer inhibitors. Objectives: We studied weight...
3.
Verstraeten R, Vos-Seda A, Boateng D, Scheuermaier K, Tempelman H, Barth R, et al.
J Am Heart Assoc
. 2024 Jan;
13(2):e029637.
PMID: 38214319
Background: HIV and antiretroviral therapy (ART) have been associated with increased cardiovascular disease (CVD) risk in high-income countries. The authors studied the longitudinal association between HIV and ART and nonlaboratory...
4.
Revell A, Wang D, Perez-Elias M, Wood R, Cogill D, Tempelman H, et al.
J Antimicrob Chemother
. 2021 Apr;
76(7):1898-1906.
PMID: 33792714
Objectives: With the goal of facilitating the use of HIV-TRePS to optimize therapy in settings with limited healthcare resources, we aimed to develop computational models to predict treatment responses accurately...
5.
Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al.
Lancet HIV
. 2021 Feb;
8(2):e77-e86.
PMID: 33539761
Background: The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal...
6.
Connell B, Hermans L, Wensing A, Schellens I, Schipper P, van Ham P, et al.
Sci Rep
. 2020 Sep;
10(1):15866.
PMID: 32985522
HIV-1 cell entry is mediated by binding to the CD4-receptor and chemokine co-receptors CCR5 (R5) or CXCR4 (X4). R5-tropic viruses are predominantly detected during early infection. A switch to X4-tropism...
7.
Godijk N, Vos A, Jongen V, Moraba R, Tempelman H, Grobbee D, et al.
Glob Heart
. 2020 Jun;
15(1):17.
PMID: 32489790
Background: Antiretroviral therapy (ART) transformed human immunodeficiency virus (HIV) infection into a chronic disease. Possible HIV-associated complications have emerged including cardiovascular diseases (CVD). Objectives: This study aims to determine the...
8.
Deville W, Tempelman H
PLoS One
. 2019 Apr;
14(4):e0215353.
PMID: 30986228
Background: HIV-self-testing (HIVST) could be a strategy to get more people tested for HIV in resource limited settings. One of the prerequisites of a successful HIVST programme is the availability...
9.
Jongen V, Lalla-Edward S, Vos A, Godijk N, Tempelman H, Grobbee D, et al.
BMC Public Health
. 2019 Mar;
19(1):341.
PMID: 30909905
Background: Hypertension is one of the most important risk factors for cardiovascular disease and has a high prevalence in South Africa and other low- and middle-income countries. However, awareness of...
10.
Revell A, Wang D, Perez-Elias M, Wood R, Tempelman H, Clotet B, et al.
J Acquir Immune Defic Syndr
. 2019 Mar;
81(2):207-215.
PMID: 30865186
Objective: Definitions of virological response vary from <50 up to 1000 copies of HIV-RNA/mL. Our previous models estimate the probability of HIV drug combinations reducing the viral load to <50...